Peter Greenleaf, Aurinia CEO
Aurinia’s board gets pushback from another shareholder as Iljin follows MKT Capital’s lead
It’s the not-so-lucky seven for Aurinia Pharmaceuticals.
Korean investor Iljin SNT is withholding support for seven of the Canadian biotech’s eight …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
